Literature DB >> 27455441

Prevalence, Serotype Distribution and Mortality Risk Associated With Group B Streptococcus Colonization of Newborns in Rural Bangladesh.

Mohammad Shahidul Islam1, Samir K Saha, Maksuda Islam, Joyanta K Modak, Rashed Shah, Radwanur R Talukder, Shams El Arifeen, Abdullah H Baqui, Gary L Darmstadt, Luke C Mullany.   

Abstract

BACKGROUND: Group B Streptococcus (GBS) is a predominant cause of early-onset neonatal sepsis globally; however, the impact of this organism on the health of newborns in South Asia is debated, due in part to a paucity of community-based assessments. We estimated the prevalence and serotypes of GBS colonization of the umbilical cord stump and the association of colonization with mortality in a population-based cohort of newborns in rural Sylhet District, Bangladesh.
METHODS: Umbilical cord swabs were collected from 646 newborns up to 3 times within the first week after birth (ages <24 hours, ~3 days, ~6 days) and processed to identify GBS serotypes.
RESULTS: GBS was isolated from 6.3% (41/646) of newborns. Sixty-one percent of the GBS colonization occurred in neonates within 24 hours of delivery. Serotypes VII (37.1%, n = 13/36) and Ia (33.3%, n = 12/36) were the most predominant colonizing GBS isolates. Other detected serotypes were Ib (11.1%, n = 4/36), II (11.1%, n = 4/36), V (5.6%, n = 2/36) and VI (2.8%, n = 1/36). Mortality risk among newborns with GBS colonization was 6.6 (95% confidence interval: 2.1-20.4) times higher than for those without GBS.
CONCLUSIONS: The overall prevalence of GBS colonization was lower than in settings, where GBS is a predominant etiology of neonatal illness. In addition, the GBS serotype distribution differed from that reported in the developed part of the world. However, further studies are needed to understand the true burden of GBS-related illness. Mortality risk was substantially increased in the presence of GBS on the umbilical stump, providing support for chlorhexidine antisepsis to the cord to prevent colonization of invasive pathogens.

Entities:  

Mesh:

Year:  2016        PMID: 27455441     DOI: 10.1097/INF.0000000000001306

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

Review 1.  Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Clin Microbiol Rev       Date:  2018-08-15       Impact factor: 26.132

2.  Prevalence of Group B Streptococcus Recto-Vaginal Colonization, Vertical Transmission, and Antibiotic Susceptibility Among Pregnant Women in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Habtamu Bekele; Adera Debella; Tamirat Getachew; Bikila Balis; Dawit Tamiru; Addis Eyeberu; Getahun Tiruye; Mohammed Abdurke Kure; Sisay Habte; Bajrond Eshetu; Lemma Demissie Regassa; Sinetibeb Mesfin; Adisu Alemu; Yadeta Dessie; Kasiye Shiferaw
Journal:  Front Public Health       Date:  2022-05-16

3.  Group B Streptococcus among Pregnant Women and Newborns in Mirzapur, Bangladesh: Colonization, Vertical Transmission, and Serotype Distribution.

Authors:  Samir K Saha; Zabed B Ahmed; Joyanta K Modak; Hakka Naziat; Shampa Saha; Mohammad A Uddin; Maksuda Islam; Abdullah H Baqui; Gary L Darmstadt; Stephanie J Schrag
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

4.  Temporal Changes in Invasive Group B Streptococcus Serotypes: Implications for Vaccine Development.

Authors:  Ziyaad Dangor; Clare L Cutland; Alane Izu; Gaurav Kwatra; Siobhan Trenor; Sanjay G Lala; Shabir A Madhi
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

Review 5.  Codevelopment of Microbiota and Innate Immunity and the Risk for Group B Streptococcal Disease.

Authors:  Julia Kolter; Philipp Henneke
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

6.  Newborn colonization and antibiotic susceptibility patterns of Streptococcus agalactiae at the University of Gondar Referral Hospital, Northwest Ethiopia.

Authors:  Mucheye Gizachew; Moges Tiruneh; Feleke Moges; Mulat Adefris; Zemene Tigabu; Belay Tessema
Journal:  BMC Pediatr       Date:  2018-11-30       Impact factor: 2.125

Review 7.  WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.

Authors:  Miwako Kobayashi; Stephanie J Schrag; Mark R Alderson; Shabir A Madhi; Carol J Baker; Ajoke Sobanjo-Ter Meulen; David C Kaslow; Peter G Smith; Vasee S Moorthy; Johan Vekemans
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

8.  Vertical transmission of group B Streptococcus and associated factors among pregnant women: a cross-sectional study, Eastern Ethiopia.

Authors:  Tesfaye Assebe Yadeta; Alemayehu Worku; Gudina Egata; Berhanu Seyoum; Dadi Marami; Yemane Berhane
Journal:  Infect Drug Resist       Date:  2018-03-13       Impact factor: 4.003

9.  Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study.

Authors:  Samir K Saha; Stephanie J Schrag; Shams El Arifeen; Luke C Mullany; Mohammad Shahidul Islam; Nong Shang; Shamim A Qazi; Anita K M Zaidi; Zulfiqar A Bhutta; Anuradha Bose; Pinaki Panigrahi; Sajid B Soofi; Nicholas E Connor; Dipak K Mitra; Rita Isaac; Jonas M Winchell; Melissa L Arvay; Maksuda Islam; Yasir Shafiq; Imran Nisar; Benazir Baloch; Furqan Kabir; Murtaza Ali; Maureen H Diaz; Radhanath Satpathy; Pritish Nanda; Bijaya K Padhi; Sailajanandan Parida; Aneeta Hotwani; M Hasanuzzaman; Sheraz Ahmed; Mohammad Belal Hossain; Shabina Ariff; Imran Ahmed; Syed Mamun Ibne Moin; Arif Mahmud; Jessica L Waller; Iftekhar Rafiqullah; Mohammad A Quaiyum; Nazma Begum; Veeraraghavan Balaji; Jasmin Halen; A S M Nawshad Uddin Ahmed; Martin W Weber; Davidson H Hamer; Patricia L Hibberd; Qazi Sadeq-Ur Rahman; Venkat Raghava Mogan; Tanvir Hossain; Lesley McGee; Shalini Anandan; Anran Liu; Kalpana Panigrahi; Asha Mary Abraham; Abdullah H Baqui
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.